1
|
Kato S, Shah A, Plesescu M, Miyata Y, Bolleddula J, Chowdhury S, Zhu X. Prediction of Human Disproportionate and Biliary Excreted Metabolites Using Chimeric Mice with Humanized Liver. Drug Metab Dispos 2020; 48:934-943. [PMID: 32665417 DOI: 10.1124/dmd.120.000128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2020] [Accepted: 07/07/2020] [Indexed: 11/22/2022] Open
Abstract
The PXB-mouse is potentially a useful in vivo model to predict human hepatic metabolism and clearance. Four model compounds, [14C]desloratadine, [3H]mianserin, cyproheptadine, and [3H]carbazeran, all reported with disproportionate human metabolites, were orally administered to PXB- or control SCID mice to elucidate the biotransformation of each of them. For [14C]desloratadine in PXB-mice, O-glucuronide of 3-hydroxydesloratadine was observed as the predominant metabolite in both the plasma and urine. Both 3-hydroxydesloratadine and its O-glucuronide were detected as major drug-related materials in the bile, whereas only 3-hydroxydesloratadine was detected in the feces, suggesting that a fraction of 3-hydroxydesloratadine in feces was derived from deconjugation of its O-glucuronide by gut microflora. This information can help understand the biliary clearance mechanism of a drug and may fill the gap in a human absorption, distribution, metabolism, and excretion study, in which the bile samples are typically not available. The metabolic profiles in PXB-mice were qualitatively similar to those reported in humans in a clinical study in which 3-hydroxydesloratadine and its O-glucuronide were major and disproportionate metabolites compared with rat, mouse, and monkey. In the control SCID mice, neither of the metabolites was detected in any matrix. Similarly, for the other three compounds, all human specific or disproportionate metabolites were detected at a high level in PXB-mice, but they were either minimally observed or not observed in the control mice. Data from these four compounds indicate that studies in PXB-mice can help predict the potential for the presence of human disproportionate metabolites (relative to preclinical species) prior to conducting clinical studies and understand the biliary clearance mechanism of a drug. SIGNIFICANCE STATEMENT: Studies in PXB-mice have successfully predicted the human major and disproportionate metabolites compared with preclinical safety species for desloratadine, mianserin, cyproheptadine, and carbazeran. In addition, biliary excretion data from PXB-mice can help illustrate the human biliary clearance mechanism of a drug.
Collapse
Affiliation(s)
- Suguru Kato
- Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (S.K., A.S., M.P., J.B., S.C., X.Z.) and Research Planning and Business Development, PhoenixBio USA Corporation, New York City, New York (Y.M.)
| | - Abhi Shah
- Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (S.K., A.S., M.P., J.B., S.C., X.Z.) and Research Planning and Business Development, PhoenixBio USA Corporation, New York City, New York (Y.M.)
| | - Mihaela Plesescu
- Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (S.K., A.S., M.P., J.B., S.C., X.Z.) and Research Planning and Business Development, PhoenixBio USA Corporation, New York City, New York (Y.M.)
| | - Yoshinari Miyata
- Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (S.K., A.S., M.P., J.B., S.C., X.Z.) and Research Planning and Business Development, PhoenixBio USA Corporation, New York City, New York (Y.M.)
| | - Jayaprakasam Bolleddula
- Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (S.K., A.S., M.P., J.B., S.C., X.Z.) and Research Planning and Business Development, PhoenixBio USA Corporation, New York City, New York (Y.M.)
| | - Swapan Chowdhury
- Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (S.K., A.S., M.P., J.B., S.C., X.Z.) and Research Planning and Business Development, PhoenixBio USA Corporation, New York City, New York (Y.M.)
| | - Xiaochun Zhu
- Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (S.K., A.S., M.P., J.B., S.C., X.Z.) and Research Planning and Business Development, PhoenixBio USA Corporation, New York City, New York (Y.M.)
| |
Collapse
|
2
|
Chau N, Kaya L, Lewis BC, Mackenzie PI, Miners JO. Drug and Chemical Glucosidation by Control Supersomes and Membranes from Spodoptera frugiperda (Sf) 9 Cells: Implications for the Apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5. Drug Metab Dispos 2018; 47:271-278. [PMID: 30541877 DOI: 10.1124/dmd.118.084947] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2018] [Accepted: 11/29/2018] [Indexed: 01/13/2023] Open
Abstract
Accumulating evidence indicates that several human UDP-glucuronosyltransferase (UGT) enzymes catalyze both glucuronidation and glucosidation reactions. Baculovirus-infected insect cells [Trichoplusia ni and Spodoptera frugiperda (Sf9)] are used widely for the expression of recombinant human UGT enzymes. Following the observation that control Supersomes (c-SUP) express a native enzyme capable of glucosidating morphine, we characterized the glucosidation of a series of aglycones with a hydroxyl (aliphatic or phenolic), carboxylic acid, or amine functional group by c-SUP and membranes from uninfected Sf9 cells. Although both enzyme sources glucosidated the phenolic substrates investigated, albeit with differing activities, differences were observed in the selectivities of the native UDP-glucosyltransferases toward aliphatic alcohols, carboxylic acids, and amines. For example, zidovudine was solely glucosidated by c-SUP. By contrast, c-SUP lacked activity toward the amines lamotrigine and trifluoperazine and did not form the acyl glucoside of mycophenolic acid, reactions all catalyzed by uninfected Sf9 membranes. Glucosidation intrinsic clearances were high for several substrates, notably 1-hydroxypyrene (∼1400-1900 µl/min⋅mg). The results underscore the importance of including control cell membranes in the investigation of drug and chemical glucosidation by UGT enzymes expressed in T. ni (High-Five) and Sf9 cells. In a coincident study, we observed that UGT1A5 expressed in Sf9, human embryonic kidney 293T, and COS7 cells lacked glucuronidation activity toward prototypic phenolic substrates. However, Sf9 cells expressing UGT1A5 glucosidated 1-hydroxypyrene with UDP-glucuronic acid as the cofactor, presumably due to the presence of UDP-glucose as an impurity. Artifactual glucosidation may explain, at least in part, a previous report of phenolic glucuronidation by UGT1A5.
Collapse
Affiliation(s)
- Nuy Chau
- Department of Clinical Pharmacology (N.C., L.K., B.C.L., P.I.M., J.O.M.) and Flinders Centre for Innovation in Cancer (B.C.L., P.I.M., J.O.M.), Flinders University College of Medicine and Public Health, Adelaide, Australia
| | - Leyla Kaya
- Department of Clinical Pharmacology (N.C., L.K., B.C.L., P.I.M., J.O.M.) and Flinders Centre for Innovation in Cancer (B.C.L., P.I.M., J.O.M.), Flinders University College of Medicine and Public Health, Adelaide, Australia
| | - Benjamin C Lewis
- Department of Clinical Pharmacology (N.C., L.K., B.C.L., P.I.M., J.O.M.) and Flinders Centre for Innovation in Cancer (B.C.L., P.I.M., J.O.M.), Flinders University College of Medicine and Public Health, Adelaide, Australia
| | - Peter I Mackenzie
- Department of Clinical Pharmacology (N.C., L.K., B.C.L., P.I.M., J.O.M.) and Flinders Centre for Innovation in Cancer (B.C.L., P.I.M., J.O.M.), Flinders University College of Medicine and Public Health, Adelaide, Australia
| | - John O Miners
- Department of Clinical Pharmacology (N.C., L.K., B.C.L., P.I.M., J.O.M.) and Flinders Centre for Innovation in Cancer (B.C.L., P.I.M., J.O.M.), Flinders University College of Medicine and Public Health, Adelaide, Australia
| |
Collapse
|